Addition Therapeutics

Addition Therapeutics

Addition Therapeutics is on a mission to fulfill the transformative promise of genomic medicine for people impacted by both chronic and rare diseases. Leveraging our breakthrough all-RNA, non-viral, LNP-based PRINT™ platform, we are overcoming the limitations of existing genetic medicine modalities to develop safer, durable, one-time therapies. Bolstered by our team of top-tier scientists and engineers, we are advancing a robust pipeline of PRINTed therapeutics that have the potential to fundamentally redefine how chronic and rare diseases are treated. Our investor syndicate includes SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation, and BEVC.

About Addition Therapeutics

Addition Therapeutics is pioneering the future of genomic medicine by harnessing the innovative all-RNA PRINT™ platform. Committed to transforming healthcare, the company aims to make genomic therapies accessible to a broader range of patients, particularly those suffering from chronic and rare diseases. The PRINT technology leverages non-viral, lipid nanoparticle-based methods to deliver precise RNA-mediated treatments, offering a safer and more durable alternative to traditional genetic medicine.

With a dedicated team of skilled scientists and engineers, Addition is actively developing a promising pipeline of PRINTed therapeutics targeting significant unmet medical needs. Their research is supported by collaborations with pharmaceutical companies and notable organizations like the Gates Foundation, showcasing the platform's versatility in addressing various health challenges. By focusing on creating one-time therapies, Addition Therapeutics seeks to redefine treatment paradigms and improve patient outcomes, ultimately striving to fulfill the promise of genomic medicine for all.

No open roles right now — view past roles below

About this page

This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Addition Therapeutics, you can claim this page to manage and enhance it.